Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/056771external-prioritypatent/WO2010033443A1/en
Application filed by Boehringer Ingelheim IntfiledCriticalBoehringer Ingelheim Int
Publication of TN2011000134A1publicationCriticalpatent/TN2011000134A1/en
The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
TN2011000134A2009-09-142011-03-15Polytherapie destinee a traiter une infection par le vhc
TN2011000134A1
(en)
Combination of at least two antiviral agents of direct action and ribavirina but not interfered, for use in the vhc treatment (Machine-translation by Google Translate, not legally binding)